Sir Chris Hoy’s interview with last week’s Sunday Times in which he said that doctors had told him that he had between two ...

Research uncovers how P-stalk ribosomes regulate cytokine responses, driving immune evasion in tumors across multiple cancer ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK ... Michael Dickinson, MBBS, FRACP, Lead of the Aggressive Lymphoma Disease Group at Peter ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 ...

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration ...

Antibodies show promise as candidates for therapeutics as well as tools for advancing mechanistic studies of the HER family receptors.

The first patient has been successfully imaged, marking a milestone in the development of this copper-based ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Olympian Chris Hoy has raised awareness of the common cancer since revealing his terminal diagnosis this weekend.